Published in Kardiol Pol on February 01, 2007
Bivalirudin during primary PCI in acute myocardial infarction. N Engl J Med (2008) 5.86
Percutaneous closure of patent foramen ovale in cryptogenic embolism. N Engl J Med (2013) 4.62
A bioabsorbable everolimus-eluting coronary stent system (ABSORB): 2-year outcomes and results from multiple imaging methods. Lancet (2009) 3.55
Randomized study to assess the effectiveness of slow- and moderate-release polymer-based paclitaxel-eluting stents for coronary artery lesions. Circulation (2003) 3.22
A bioabsorbable everolimus-eluting coronary stent system for patients with single de-novo coronary artery lesions (ABSORB): a prospective open-label trial. Lancet (2008) 3.12
Pulsatile but not steady component of blood pressure predicts cardiovascular events in coronary patients. Hypertension (2008) 2.89
Evaluation of the second generation of a bioresorbable everolimus-eluting vascular scaffold for the treatment of de novo coronary artery stenosis: 12-month clinical and imaging outcomes. J Am Coll Cardiol (2011) 2.85
Bivalirudin in patients undergoing primary angioplasty for acute myocardial infarction (HORIZONS-AMI): 1-year results of a randomised controlled trial. Lancet (2009) 2.82
Effects of the direct lipoprotein-associated phospholipase A(2) inhibitor darapladib on human coronary atherosclerotic plaque. Circulation (2008) 2.62
Evaluation of the second generation of a bioresorbable everolimus drug-eluting vascular scaffold for treatment of de novo coronary artery stenosis: six-month clinical and imaging outcomes. Circulation (2010) 2.54
Prognostic impact of staged versus "one-time" multivessel percutaneous intervention in acute myocardial infarction: analysis from the HORIZONS-AMI (harmonizing outcomes with revascularization and stents in acute myocardial infarction) trial. J Am Coll Cardiol (2011) 2.49
Five-year clinical and functional multislice computed tomography angiographic results after coronary implantation of the fully resorbable polymeric everolimus-eluting scaffold in patients with de novo coronary artery disease: the ABSORB cohort A trial. JACC Cardiovasc Interv (2013) 2.32
Fractional diastolic and systolic pressure in the ascending aorta are related to the extent of coronary artery disease. Am J Hypertens (2004) 2.21
Clinical impact of thrombectomy in acute ST-elevation myocardial infarction: an individual patient-data pooled analysis of 11 trials. Eur Heart J (2009) 2.19
Frequency and predictors of stent thrombosis after percutaneous coronary intervention in acute myocardial infarction. Circulation (2011) 2.18
Long-term follow-up of mesh-covered stent implantation in patients with ST-segment elevation myocardial infarction. Kardiol Pol (2013) 2.04
Proximal endovascular flow blockage for cerebral protection during carotid artery stenting: results from a prospective multicenter registry. J Endovasc Ther (2005) 2.03
Acute and late outcomes of unprotected left main stenting in comparison with surgical revascularization. J Am Coll Cardiol (2008) 1.99
Randomized trial of atopaxar in the treatment of patients with coronary artery disease: the lessons from antagonizing the cellular effect of Thrombin–Coronary Artery Disease Trial. Circulation (2011) 1.96
Direct intramyocardial plasmid vascular endothelial growth factor-A165 gene therapy in patients with stable severe angina pectoris A randomized double-blind placebo-controlled study: the Euroinject One trial. J Am Coll Cardiol (2005) 1.92
Comparison of in vivo acute stent recoil between the bioabsorbable everolimus-eluting coronary stent and the everolimus-eluting cobalt chromium coronary stent: insights from the ABSORB and SPIRIT trials. Catheter Cardiovasc Interv (2007) 1.77
Paclitaxel-eluting stents versus bare-metal stents in acute myocardial infarction. N Engl J Med (2009) 1.72
Impact of in-hospital major bleeding on late clinical outcomes after primary percutaneous coronary intervention in acute myocardial infarction the HORIZONS-AMI (Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction) trial. J Am Coll Cardiol (2011) 1.72
Comparison of in vivo acute stent recoil between the bioresorbable everolimus-eluting coronary scaffolds (revision 1.0 and 1.1) and the metallic everolimus-eluting stent. Catheter Cardiovasc Interv (2011) 1.62
The value of ECG parameters in estimating myocardial injury and establishing prognosis in patients with acute pulmonary embolism. Kardiol Pol (2011) 1.60
Transthoracic, harmonic mode, contrast enhanced color Doppler echocardiography in detection of restenosis after percutaneous coronary interventions. Prospective evaluation verified by coronary angiography. Eur J Echocardiogr (2004) 1.59
How often pulmonary embolism mimics acute coronary syndrome? Kardiol Pol (2011) 1.58
Early abciximab use in ST-elevation myocardial infarction treated with primary percutaneous coronary intervention improves long-term outcome. Data from EUROTRANSFER Registry. Kardiol Pol (2010) 1.54
Angiographic geometric changes of the lumen arterial wall after bioresorbable vascular scaffolds and metallic platform stents at 1-year follow-up. JACC Cardiovasc Interv (2011) 1.53
[Management of acute myocardial infarction in patients presenting with persistent ST-segment elevation]. G Ital Cardiol (Rome) (2009) 1.52
Inter-individual variability in response to clopidogrel in patients with coronary artery disease. Kardiol Pol (2005) 1.52
Clinical outcomes following stent thrombosis occurring in-hospital versus out-of-hospital: results from the HORIZONS-AMI (Harmonizing Outcomes with Revascularization and Stents in Acute Myocardial Infarction) trial. J Am Coll Cardiol (2012) 1.51
Relationship between chronic obstructive pulmonary disease and in-hospital management and outcomes in patients with acute myocardial infarction. Kardiol Pol (2010) 1.48
The prognostic value of ST-segment elevation in the lead aVR in patients with acute pulmonary embolism. Kardiol Pol (2011) 1.48
Primary percutaneous coronary intervention during on- vs off-hours in patients with ST-elevation myocardial infarction. Results from EUROTRANSFER Registry. Kardiol Pol (2011) 1.47
Surgical ablation for atrial fibrillation using the Ex-Maze III procedure on the beating heart in patients undergoing mitral valve surgery. Kardiol Pol (2011) 1.44
Synergistic effects of asymmetrical dimethyl-L-arginine accumulation and endothelial progenitor cell deficiency on renal function decline during a 2-year follow-up in stable angina. Nephrol Dial Transplant (2009) 1.43
Safety and tolerability of atopaxar in the treatment of patients with acute coronary syndromes: the lessons from antagonizing the cellular effects of Thrombin–Acute Coronary Syndromes Trial. Circulation (2011) 1.43
Plasma B-type natriuretic peptide as a marker of myocardial asynchrony. Cardiology (2009) 1.42
Influence of different antiplatelet treatment regimens for primary percutaneous coronary intervention on all-cause mortality. Eur Heart J (2009) 1.41
Comparison of in vivo eccentricity and symmetry indices between metallic stents and bioresorbable vascular scaffolds: insights from the ABSORB and SPIRIT trials. Catheter Cardiovasc Interv (2011) 1.41
Femoral vascular closure device use, bivalirudin anticoagulation, and bleeding after primary angioplasty for STEMI: results from the HORIZONS-AMI trial. Catheter Cardiovasc Interv (2014) 1.40
Predictors of infarct-related artery patency following combined lytic therapy in patients with ST-segment elevation myocardial infarction treated with immediate percutaneous coronary intervention. Kardiol Pol (2011) 1.40
Increased prevalence of cardiovascular risk factors in patients with acute coronary syndrome and indications for treatment with oral anticoagulation. Kardiol Pol (2011) 1.40
Impact of direct stenting on outcome of patients with ST-elevation myocardial infarction transferred for primary percutaneous coronary intervention (from the EUROTRANSFER registry). Catheter Cardiovasc Interv (2014) 1.40
Rationale and design of the MGuard for acute ST elevation reperfusion MASTER trial. Catheter Cardiovasc Interv (2013) 1.40
Efficacy and Safety of Novel NovaCross Microcatheter for Chronic Total Occlusions: First-in-Human Study. J Invasive Cardiol (2016) 1.39
Giant drug-induced QT prolongation > 800 ms with alternans of terminal portion of T wave and J wave in a normothermic patient. Kardiol Pol (2013) 1.39
Impact of infarct related artery patency after early abciximab administration on one-year mortality in patients with ST-segment elevation myocardial infarction (data from the EUROTRANSFER Registry). Kardiol Pol (2012) 1.39
Clinical outcomes in patients after surgical and transcatheter aortic valve replacement. Pol Arch Med Wewn (2015) 1.39
Percutaneous peripheral interventions in patients with multivessel coronary artery disease. Kardiol Pol (2010) 1.38
Prognostic significance of ST segment changes in lead aVR in patients with acute inferior myocardial infarction with ST segment elevation. Kardiol Pol (2012) 1.37
Acute hyperglycaemia and inflammation in patients with ST segment elevation myocardial infarction. Kardiol Pol (2013) 1.37
European perspective in the recanalisation of Chronic Total Occlusions (CTO): consensus document from the EuroCTO Club. EuroIntervention (2007) 1.36
Pretreatment with prasugrel in non-ST-segment elevation acute coronary syndromes. N Engl J Med (2013) 1.32
Incomplete stent apposition after implantation of paclitaxel-eluting stents or bare metal stents: insights from the randomized TAXUS II trial. Circulation (2005) 1.28
When is door-to-balloon time critical? Analysis from the HORIZONS-AMI (Harmonizing Outcomes with Revascularization and Stents in Acute Myocardial Infarction) and CADILLAC (Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications) trials. J Am Coll Cardiol (2010) 1.28
Dynamics of vessel wall changes following the implantation of the absorb everolimus-eluting bioresorbable vascular scaffold: a multi-imaging modality study at 6, 12, 24 and 36 months. EuroIntervention (2014) 1.26
Plaque composition and clinical outcomes in acute coronary syndrome patients with metabolic syndrome or diabetes. JACC Cardiovasc Imaging (2012) 1.24
A comparison of the conformability of everolimus-eluting bioresorbable vascular scaffolds to metal platform coronary stents. JACC Cardiovasc Interv (2010) 1.23
First serial assessment at 6 months and 2 years of the second generation of absorb everolimus-eluting bioresorbable vascular scaffold: a multi-imaging modality study. Circ Cardiovasc Interv (2012) 1.19
Selection criteria for drug-eluting versus bare-metal stents and the impact of routine angiographic follow-up: 2-year insights from the HORIZONS-AMI (Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction) trial. J Am Coll Cardiol (2010) 1.16
The function of the left ventricle after complete multivessel one-stage percutaneous coronary intervention in patients with acute myocardial infarction. J Invasive Cardiol (2004) 1.15
Role of clopidogrel loading dose in patients with ST-segment elevation myocardial infarction undergoing primary angioplasty: results from the HORIZONS-AMI (harmonizing outcomes with revascularization and stents in acute myocardial infarction) trial. J Am Coll Cardiol (2009) 1.12
Bioresorbable vascular scaffolds in patients with acute coronary syndromes: the POLAR ACS study. Pol Arch Med Wewn (2014) 1.11
Paclitaxel-eluting stents compared with bare metal stents in diabetic patients with acute myocardial infarction: the Harmonizing Outcomes with Revascularization and Stents in Acute Myocardial Infarction (HORIZONS-AMI) trial. Circ Cardiovasc Interv (2011) 1.11
Prospective, Randomized, Multicenter Evaluation of a Polyethylene Terephthalate Micronet Mesh-Covered Stent (MGuard) in ST-Segment Elevation Myocardial Infarction: The MASTER Trial. J Am Coll Cardiol (2012) 1.09
Long-term impact of chronic kidney disease in patients with ST-segment elevation myocardial infarction treated with primary percutaneous coronary intervention: the HORIZONS-AMI (Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction) trial. JACC Cardiovasc Interv (2011) 1.08
Comment on "Correlation between the activity of the autonomic nervous system and endothelial function in patients with acute coronary syndrome". Pol Arch Med Wewn (2015) 1.07
Serial analysis of the malapposed and uncovered struts of the new generation of everolimus-eluting bioresorbable scaffold with optical coherence tomography. JACC Cardiovasc Interv (2011) 1.05
Relationship between palpography and virtual histology in patients with acute coronary syndromes. JACC Cardiovasc Imaging (2012) 1.04
Impact of anemia on clinical outcomes of patients with ST-segment elevation myocardial infarction in relation to gender and adjunctive antithrombotic therapy (from the HORIZONS-AMI trial). Am J Cardiol (2010) 1.04
Contemporary practice and technical aspects in coronary intervention with bioresorbable scaffolds: a European perspective. EuroIntervention (2015) 1.04
Effect of switching antithrombin agents for primary angioplasty in acute myocardial infarction: the HORIZONS-SWITCH analysis. J Am Coll Cardiol (2011) 1.01
Altered plasma fibrin clot properties are associated with in-stent thrombosis. Arterioscler Thromb Vasc Biol (2009) 1.00
More aggressive pharmacological treatment may improve clinical outcome in patients with non-ST-elevation acute coronary syndromes treated conservatively. Coron Artery Dis (2007) 0.99
Three-year results of clinical follow-up after a bioresorbable everolimus-eluting scaffold in patients with de novo coronary artery disease: the ABSORB trial. EuroIntervention (2010) 0.99
Head-to-head comparison of the neointimal response between metallic and bioresorbable everolimus-eluting scaffolds using optical coherence tomography. JACC Cardiovasc Interv (2011) 0.97
Assessment of the absorption process following bioabsorbable everolimus-eluting stent implantation: temporal changes in strain values and tissue composition using intravascular ultrasound radiofrequency data analysis. A substudy of the ABSORB clinical trial. EuroIntervention (2009) 0.96
Acute myocardial infarction and a new ABCC6 mutation in a 16-year-old boy with pseudoxanthoma elasticum. Int J Cardiol (2006) 0.96
[ESC guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. The Task Force for the management of acute coronary syndromes (ACS) in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC)]. G Ital Cardiol (Rome) (2012) 0.95
In-hospital management and mortality in elderly patients with non-ST-segment elevation acute coronary syndromes treated in centers without on-site invasive facilities. Cardiol J (2008) 0.94